177Lu-PSMA radio-ligand therapy

被引：0
|
作者：
Chanchou, M. [1 ]
Giraudet, A. L. [2 ]
机构：
[1] UCA, Serv Med Nucl,Inserm, Ctr Jean Perrin, UMR 1240,IMoST, 58 Rue Montalembert, F-63011 Clermont Ferrand, France
[2] Ctr Leon Berard, Serv Med Nucl, Lyon, France
来源：
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2023年 / 47卷 / 06期
关键词：
Lu-177-PSMA; RLT; PSMA-PET; MCRPC; RESISTANT PROSTATE-CANCER; TRIAL;
D O I：
10.1016/j.mednuc.2023.09.005
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Lutetium-177-labeled PSMA radio-ligand therapy is becoming more and more widespread in nuclear medicine departments, in France and around the world. Practitioners must master specificities of this treatment in order to develop this type of therapeutic care in the best conditions. This summary article presents the methods of carrying out treatment with Lu-177-PSMA in nuclear medicine departments as well as the various current clinical research subjects concerning this theme. (C) 2023 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：316 / 322
页数：7
相关论文
共 50 条
  • [1] Dosimetry of 177Lu-PSMA
    Serrano, B.
    Amblard, R.
    Koulibaly, P. M.
    Gasteuil, J.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2023, 47 (06): : 323 - 332
  • [2] 177Lu-PSMA Radioligand Therapy for Prostate Cancer
    Fendler, Wolfgang P.
    Rahbar, Kambiz
    Herrmann, Ken
    Kratochwil, Clemens
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (08) : 1196 - 1200
  • [3] PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy
    Hartrampf, Philipp E.
    Serfling, Sebastian E.
    Michalski, Kerstin
    Buck, Andreas K.
    Werner, Rudolf A.
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (01) : 69 - 76
  • [4] Optimisation of the Radiation Dosimetry Protocol in 177Lu-PSMA Therapy
    Mink, M.
    Peters, S. M.
    Prive, B. M.
    de Bakker, M.
    Muselaers, C. H.
    Mehra, N.
    Witjes, J. A.
    Gotthardt, M.
    Timmermans, C. W.
    Nagarajah, J.
    Konijnenberg, M. W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S73 - S73
  • [5] Radionuclide Therapy With 177Lu-PSMA in a Patient With Hepatocellular Carcinoma
    Pretet, Valentin
    Giraudet, Anne Laure
    Vergnaud, Laure
    Paquet, Emilie
    Kryza, David
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 584 - 586
  • [6] Incorporation Of 177Lu During Care Of 177Lu-PSMA And 177Lu-DOTATATE Therapy Patients
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Kratzel, U.
    Baumgarten, J.
    Ngoc, C. Nguyen
    Garayev, E.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S842 - S843
  • [7] Experience of Use of 177Lu-PSMA in Brazil
    Viana, A.
    Nabinger, P.
    Madke, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S400 - S400
  • [8] Optimal sampling schedules for kidney dosimetry for 177Lu-PSMA therapy
    Rinscheid, Andreas
    Allmann, Anne
    Allmann, Jakob
    Eberhardt, Nina
    Eiber, Matthias
    Kletting, Peter
    Beer, Ambros
    Glatting, Gerhard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [9] Urinary excretion kinetics of 177Lu-PSMA
    de Bakker, M.
    Dominicus, N.
    Meeuwis, A.
    Janssen, M. J. R.
    Konijnenberg, M. W.
    Nagarajah, J.
    Peters, S. M. B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S36 - S36
  • [10] PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy
    Murthy, Vishnu
    Allen-Auerbach, Martin
    Lam, Richard
    Owen, Dawn
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (09) : 1502 - 1503
12345